Gabapentin: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: {{subpages}} '''Gabapentin''' is a medication used for epilepsy and postherpetic neuralgia. Regarding the treatment of diabetic neuropathy or postherpetic neuralgia, [[ran...) |
imported>Robert Badgett No edit summary |
||
| Line 2: | Line 2: | ||
'''Gabapentin''' is a medication used for [[epilepsy]] and [[postherpetic neuralgia]]. | '''Gabapentin''' is a medication used for [[epilepsy]] and [[postherpetic neuralgia]]. | ||
==Effectiveness== | |||
Regarding the treatment of [[diabetic neuropathy]] or [[postherpetic neuralgia]], [[randomized controlled trial]] found that while gabapentin was not as effective as morphine, the combination of the two medications was more effective than either alone and allowed for a lower dose of morphine.<ref name="pmid15800228">{{cite journal |author=Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL |title=Morphine, gabapentin, or their combination for neuropathic pain |journal=N. Engl. J. Med. |volume=352 |issue=13 |pages=1324–34 |year=2005 |month=March |pmid=15800228 |doi=10.1056/NEJMoa042580 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=15800228&promo=ONFLNS19 |issn=}}</ref> | Regarding the treatment of [[diabetic neuropathy]] or [[postherpetic neuralgia]], [[randomized controlled trial]] found that while gabapentin was not as effective as morphine, the combination of the two medications was more effective than either alone and allowed for a lower dose of morphine.<ref name="pmid15800228">{{cite journal |author=Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL |title=Morphine, gabapentin, or their combination for neuropathic pain |journal=N. Engl. J. Med. |volume=352 |issue=13 |pages=1324–34 |year=2005 |month=March |pmid=15800228 |doi=10.1056/NEJMoa042580 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=15800228&promo=ONFLNS19 |issn=}}</ref> | ||
Regarding the treatment of [[low back pain]], a [[systematic review]] found that gabapentin may be effective.<ref name="pmid17909211">{{cite journal |author=Chou R, Huffman LH |title=Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline |journal=Ann. Intern. Med. |volume=147 |issue=7 |pages=505–14 |year=2007 |month=October |pmid=17909211 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=reprint&pmid=17909211 |issn=}}</ref> | |||
For partial [[epilepsy]], the SANAD [[randomized controlled trial]] compared [[carbamazepine]], [[gabapentin]], [[lamotrigine]], [[oxcarbazepine]], or [[topiramate]] and concluded that gabapentin was less effective.<ref name="pmid17382827">{{cite journal |author=Marson AG, Al-Kharusi AM, Alwaidh M, ''et al'' |title=The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial |journal=Lancet |volume=369 |issue=9566 |pages=1000–15 |year=2007 |month=March |pmid=17382827 |pmc=2080688 |doi=10.1016/S0140-6736(07)60460-7 |url=http://linkinghub.elsevier.com/retrieve/pii/S0140-6736(07)60460-7 |issn=}}</ref> | |||
==Legal action== | |||
In the case of ''United States ex. rel David Franklin vs. Pfizer, Inc., and Parke-Davis, Division of Warner-Lambert Company'', "in 2004 the Pfizer subsidiary Warner-Lambert settled litigation and admitted guilt in connection to charges that during the 1990s it violated federal regulations by promoting the drug for [[pain]], psychiatric conditions, [[migraine]], and other unapproved uses."<ref name="pmid16908919">{{cite journal |author=Steinman MA, Bero LA, Chren MM, Landefeld CS |title=Narrative review: the promotion of gabapentin: an analysis of internal industry documents |journal=Ann. Intern. Med. |volume=145 |issue=4 |pages=284–93 |year=2006 |month=August |pmid=16908919 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=reprint&pmid=16908919 |issn=}}</ref> | In the case of ''United States ex. rel David Franklin vs. Pfizer, Inc., and Parke-Davis, Division of Warner-Lambert Company'', "in 2004 the Pfizer subsidiary Warner-Lambert settled litigation and admitted guilt in connection to charges that during the 1990s it violated federal regulations by promoting the drug for [[pain]], psychiatric conditions, [[migraine]], and other unapproved uses."<ref name="pmid16908919">{{cite journal |author=Steinman MA, Bero LA, Chren MM, Landefeld CS |title=Narrative review: the promotion of gabapentin: an analysis of internal industry documents |journal=Ann. Intern. Med. |volume=145 |issue=4 |pages=284–93 |year=2006 |month=August |pmid=16908919 |doi= |url=http://www.annals.org/cgi/pmidlookup?view=reprint&pmid=16908919 |issn=}}</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 21:15, 21 June 2008
Gabapentin is a medication used for epilepsy and postherpetic neuralgia.
Effectiveness
Regarding the treatment of diabetic neuropathy or postherpetic neuralgia, randomized controlled trial found that while gabapentin was not as effective as morphine, the combination of the two medications was more effective than either alone and allowed for a lower dose of morphine.[1]
Regarding the treatment of low back pain, a systematic review found that gabapentin may be effective.[2]
For partial epilepsy, the SANAD randomized controlled trial compared carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate and concluded that gabapentin was less effective.[3]
Legal action
In the case of United States ex. rel David Franklin vs. Pfizer, Inc., and Parke-Davis, Division of Warner-Lambert Company, "in 2004 the Pfizer subsidiary Warner-Lambert settled litigation and admitted guilt in connection to charges that during the 1990s it violated federal regulations by promoting the drug for pain, psychiatric conditions, migraine, and other unapproved uses."[4]
References
- ↑ Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL (March 2005). "Morphine, gabapentin, or their combination for neuropathic pain". N. Engl. J. Med. 352 (13): 1324–34. DOI:10.1056/NEJMoa042580. PMID 15800228. Research Blogging.
- ↑ Chou R, Huffman LH (October 2007). "Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline". Ann. Intern. Med. 147 (7): 505–14. PMID 17909211. [e]
- ↑ Marson AG, Al-Kharusi AM, Alwaidh M, et al (March 2007). "The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial". Lancet 369 (9566): 1000–15. DOI:10.1016/S0140-6736(07)60460-7. PMID 17382827. PMC 2080688. Research Blogging.
- ↑ Steinman MA, Bero LA, Chren MM, Landefeld CS (August 2006). "Narrative review: the promotion of gabapentin: an analysis of internal industry documents". Ann. Intern. Med. 145 (4): 284–93. PMID 16908919. [e]